What do urologists think about using MRI in prostate cancer diagnosis and management today?

Staff at the Urologic Oncology Branch of the National Cancer Institute have just published the results of a survey evaluating current knowledge of (some) specialist urologists and urologic oncologists about the roles of MRI scanning in the diagnosis of prostate cancer and how they are integrating the use of MRI scanning and MR-guided biopsies into their clinical practice. … READ MORE …

Men initially diagnosed with de novo metastatic prostate cancer are living longer

A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …

CAR-T used in treatment of two men with mCRPC at UPenn

On a CureTalks conversation earlier today with Dr. Carl June of the University of Pennsylvania (UPenn), we learned that his team had very recently treated two men with metastatic, castration-resistant prostate cancer (mCRPC) using chimeric antibody receptor T-cell therapy (CAR-T). … READ MORE …

Personality and its impact on prostate cancer and its treatment

Your sitemaster is going to write this commentary with as much tact as he can muster but he is aware that this is going to be a very sensitive subject for some readers to deal with. … READ MORE …

TRT in treatment for hypogonadism and prostate cancer risk

Discussions about the pros and cons of testosterone replacement therapy (TRT) in relation to (a) stimulating risk for prostate cancer in men who have not been diagnosed and (b) recurrence of prostate cancer among men who have been diagnosed and treated often aren’t entirely clear about a very key factor. … READ MORE …

Where the cancer is in your prostate may really matter (sometimes)

A new article in the upcoming December issue of the Journal of Urology has shown that, for men with higher risk prostate cancers, tumors found in the transition zone of the prostate are less “risky” than the same types of cancer when they occur in the peripheral and central zones. … READ MORE …

A specific subset of men with a specific genetic variation respond to non-steroidal CYP17A1 inhibition

Just over a year ago, we reported on a paper by Hearn et al. that had shown that a specific inherited mutation in the HSD3B1 gene seemed to be associated with a more aggressive form of prostate cancer that was less responsive to treatment with androgen deprivation therapy (ADT). … READ MORE …